Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Operating Income of $340.99 million for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $340.99M | +13508.9% |
| 2024 | -$2.54M | +97.5% |
| 2023 | -$103.71M | +30.1% |
| 2022 | -$148.44M | +16.5% |
| 2021 | -$177.72M | -1.7% |
| 2020 | -$174.76M | -75.7% |
| 2019 | -$99.45M | -5.6% |
| 2018 | -$94.22M | -64.1% |
| 2017 | -$57.41M | -18.1% |
| 2016 | -$48.61M | -23.2% |
| 2015 | -$39.44M | +13.8% |
| 2014 | -$45.77M | -49.0% |
| 2013 | -$30.72M | +9.4% |
| 2012 | -$33.89M | +31.7% |
| 2011 | -$49.59M | -44.3% |
| 2010 | -$34.36M | -150.1% |
| 2009 | -$13.74M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.59M | +284.7% | -0.7% |
| June 30, 2025 | $29.79M | +240.0% | +40.3% |
| March 31, 2025 | $21.23M | +246.5% | +176.0% |
| September 30, 2024 | $7.69M | +164.5% | -12.2% |
| June 30, 2024 | $8.76M | +142.3% | +160.5% |
| March 31, 2024 | -$14.49M | +49.0% | -21.5% |
| September 30, 2023 | -$11.92M | +31.7% | +42.4% |
| June 30, 2023 | -$20.70M | +40.4% | +27.1% |
- BIOCRYST PHARMACEUTICALS INC showed an increase of +13508.9% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, BIOCRYST PHARMACEUTICALS INC’s operating income has grown by 2582.3% (from -$13.74 million to $340.99 million).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: